Skip to main content
. 2020 Dec 15;95(24):e3428–e3437. doi: 10.1212/WNL.0000000000010863

Figure 3. Concentrations of caffeine in matched plasma and CSF samples of LRRK2 Cohort Consortium (LCC) participants.

Figure 3

Concentrations of caffeine in matched plasma (A) and CSF (B) samples of LCC participants by LRRK2 and Parkinson disease (PD) status, adjusted for age, sex, and study site cohort. UC = unaffected controls.